166 related articles for article (PubMed ID: 27207511)
21. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ
Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105
[TBL] [Abstract][Full Text] [Related]
22. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
[TBL] [Abstract][Full Text] [Related]
23. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
[TBL] [Abstract][Full Text] [Related]
24. Rationale for leptin-replacement therapy for severe lipodystrophy.
Oral EA; Chan JL
Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
[TBL] [Abstract][Full Text] [Related]
25. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
[TBL] [Abstract][Full Text] [Related]
26. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults.
Baicy K; London ED; Monterosso J; Wong ML; Delibasi T; Sharma A; Licinio J
Proc Natl Acad Sci U S A; 2007 Nov; 104(46):18276-9. PubMed ID: 17986612
[TBL] [Abstract][Full Text] [Related]
27. The Effects of Leptin Replacement on Neural Plasticity.
Paz-Filho GJ
Neural Plast; 2016; 2016():8528934. PubMed ID: 26881138
[TBL] [Abstract][Full Text] [Related]
28. Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy.
Muniyappa R; Abel BS; Asthana A; Walter MF; Cochran EK; Remaley AT; Skarulis MC; Gorden P; Brown RJ
J Clin Lipidol; 2017; 11(2):543-550. PubMed ID: 28502512
[TBL] [Abstract][Full Text] [Related]
29. W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?
Mantzoros CS
Endocr Pract; 2010; 16(2):162-6. PubMed ID: 20350904
[No Abstract] [Full Text] [Related]
30. Lymphoma in acquired generalized lipodystrophy.
Brown RJ; Chan JL; Jaffe ES; Cochran E; DePaoli AM; Gautier JF; Goujard C; Vigouroux C; Gorden P
Leuk Lymphoma; 2016; 57(1):45-50. PubMed ID: 25864863
[TBL] [Abstract][Full Text] [Related]
31. Metreleptin worked in a diabetic woman with a history of hematopoietic stem cell transplantation (HSCT) during infancy: further support for the concept of 'HSCT-associated lipodystrophy'.
Adachi M; Muroya K; Hanakawa J; Asakura Y
Endocr J; 2021 Apr; 68(4):399-407. PubMed ID: 33229817
[TBL] [Abstract][Full Text] [Related]
32. Ghrelin modulates brain activity in areas that control appetitive behavior.
Malik S; McGlone F; Bedrossian D; Dagher A
Cell Metab; 2008 May; 7(5):400-9. PubMed ID: 18460331
[TBL] [Abstract][Full Text] [Related]
33. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
Vatier C; Fetita S; Boudou P; Tchankou C; Deville L; Riveline J; Young J; Mathivon L; Travert F; Morin D; Cahen J; Lascols O; Andreelli F; Reznik Y; Mongeois E; Madelaine I; Vantyghem M; Gautier J; Vigouroux C
Diabetes Obes Metab; 2016 Jul; 18(7):693-7. PubMed ID: 26584826
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
[TBL] [Abstract][Full Text] [Related]
35. Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy.
Williamson DA; Ravussin E; Wong ML; Wagner A; Dipaoli A; Caglayan S; Ozata M; Martin C; Walden H; Arnett C; Licinio J
Appetite; 2005 Aug; 45(1):75-80. PubMed ID: 15949871
[TBL] [Abstract][Full Text] [Related]
36. Treatment Options for Lipodystrophy in Children.
Mainieri F; Tagi VM; Chiarelli F
Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
[TBL] [Abstract][Full Text] [Related]
37. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.
Meral R; Malandrino N; Walter M; Neidert AH; Muniyappa R; Oral EA; Brown RJ
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1739-e1751. PubMed ID: 34677608
[TBL] [Abstract][Full Text] [Related]
38. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
Lebastchi J; Ajluni N; Neidert A; Oral EA
J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101
[TBL] [Abstract][Full Text] [Related]
39. Leptin therapy in a congenital leptin-deficient patient leads to acute and long-term changes in homeostatic, reward, and food-related brain areas.
Frank S; Heni M; Moss A; von Schnurbein J; Fritsche A; Häring HU; Farooqi S; Preissl H; Wabitsch M
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1283-7. PubMed ID: 21593110
[TBL] [Abstract][Full Text] [Related]
40. Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes.
Kushchayeva YS; Kushchayev SV; Startzell M; Cochran E; Auh S; Dai Y; Lightbourne M; Skarulis M; Brown RJ
J Clin Endocrinol Metab; 2019 Jun; 104(6):2216-2228. PubMed ID: 30657911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
